Table 1_Efficacy and safety of ropeginterferon in myeloproliferative neoplasms: a systematic review and meta-analysis.docx

A proportional meta-analysis was conducted for selected outcomes, including complete hematologic response (CHR), partial molecular response (PMR), and grade ≥3 cytopenias.</p>Results<p>A total of 18 studies involving 1,836 patients were included. Pooled analysis demonstrated that CHR rates increased over time, from 26% at 3 months to 59% at 12 months, with an overall pooled estimate of 56% (95% CI: 46%–66%). PMR was achieved in 37% of patients (95% CI: 20%–59%), although with substantial heterogeneity.

Molecular responses were supported by consistent reductions in JAK2 allele burden across studies. Clinical outcomes showed improvements in spleen size and symptom burden in several cohorts. Ropeginterferon was generally well tolerated.

The pooled proportion of grade ≥3 cytopenias was 3% (95% CI: 1%–10%), and severe hepatotoxicity was uncommon, typically occurring in ≤5% of patients. Most adverse events were low grade, with infrequent treatment discontinuations.</p>Conclusion<p>RopegIFN-α2b demonstrates favorable efficacy and safety profiles in patients with MPNs, especially in PV, with evidence of progressive hematologic and molecular responses over time.

These findings support its role as a potentially disease-modifying therapy, although further standardized and long-term studies, focusing on ET and MF, are needed.</p>Systematic Review Registration<p>crd.york.ac.uk/PROSPERO/view/CRD420261337306, identifier CRD420261337306.</p>